Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Oncology innovations, obesity medicines, an uptick for mergers and acquisitions, regulation for artificial intelligence applications and growing consumerization are expected to be key topics.
The Open Targets consortium was founded in 2014 to translate insights from genetics and functional genomics into identifying and prioritizing therapeutic targets. We highlight key achievements and insights stemming from this partnership of academic and industry scientists.
New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.
Jason Chin, head of Cambridgeâs Centre for Chemical & Synthetic Biology and CSO of Constructive Bio, discusses the role for unnatural amino acids in biologic therapies.
